File:Mainz.BioNTechSE.20200731.jpg · Wikimedia Commons · See Wikimedia Commons
BioNTech
Sign in to saveAlso known as Biopharmaceutical New Technologies, BioNTech SE, BioNTech AG, BNT, BNTX
entreprise allemande de biotechnologie
OverviewAI-generated
BioNTech SE, also known as Biopharmaceutical New Technologies, is an active company established in 2008. Headquartered in Mainz, Germany, the organization operates within the biological products industry. It is listed on the Nasdaq exchange under the ticker symbol BNTX.
The company employs 1,300 people and maintains a total asset value of 797,647,000. Its financial records indicate a total revenue of 127,575,000, alongside various net profit figures including -179,172,000, -47,662,000, and -85,950,000. Operating income has also varied, with recorded amounts of -181,518,000, -53,854,000, and -61,277,000.
Synthesized by Vinony from 38 facts across 6 sources: Wikidata, GLEIF, SEC EDGAR, ROR, Firecrawl, Vinony graph. Generated from structured data (not the Wikipedia text) and checked against those facts — may still contain errors.
Key facts
- Company.name
- BioNTech SE
- Company.logo
- BioNTech logo.svg
- Company.image
- Mainz.BioNTechSE.20200731.jpg
- Company.image_caption
- Headquarters in Mainz
- Company.type
- Public company
- Company.industry
- Biotechnology
- Company.hq_location_city
- Mainz
- Company.hq_location_country
- Germany
- Company.num_locations
- 17
- Company.num_locations_year
- 2024
- Company.area_served
- Worldwide
- Company.products
- Pfizer-BioNTech COVID-19 vaccine, Immunotherapy and vaccine candidates
- Company.services
- Immunotherapy
- Company.revenue
- billion
- Company.revenue_year
- 2025
- Company.operating_income
- €−1.40 billion
- Company.income_year
- 2025
- Company.net_income
- €−1.14 billion
via Wikipedia infobox
Company
BNTX- Industry
- Biological Products, (No Diagnostic Substances)
- Exchange
- Nasdaq
- State of incorporation
- 2M
- Entity type
- other
- Latest filing
- 6-K · 2026-06-01
- Jurisdiction
- DE
- Headquarters
- Mainz, DE
Research organization · ROR
- Type
- Company
- Founded
- 2008
- Location
- Mainz, Germany
- Also known as
- Biopharmaceutical New Technologies
- Status
- Active
GRID grid.434484.b · ISNI 0000 0004 4692 2203
Wikidata facts
- Instance of
- enterprise
- Official name
- BioNTech AG
- Country
- Germany
- Founded by
- Uğur Şahin
- Headquarters
- Mainz
- CEO
- Uğur Şahin
- Industry
- pharmaceutical industry
- Employees
- 1300
- Revenue
- 61598000
- Stock exchange
- Nasdaq
- Legal form
- Societas Europaea
- Country of origin
- Germany
- Official website
- biontech.de
- Image
- Mainz.BioNTechSE.20200731.jpg
Show 13 more facts
- inception
- 2008-06-00
- Commons category
- BioNTech
- significant person
- Katalin Karikó
- on focus list of Wikimedia project
- WikiProject COVID-19
- net profit
- -85950000
- total assets
- 374713000
- board member
- Uğur Şahin
- operating income
- -61277000
- total equity
- -48206000
- product or material produced
- Pfizer–BioNTech COVID-19 vaccine
- topic's main category
- Category:BioNTech
- social media followers
- 82448
- location of formation
- Mainz
Sources (8)
via Wikidata · CC0
Article · Français
BioNTech est une société allemande de biotechnologie spécialisée dans le développement et la fabrication d'immunothérapies actives dans le traitement des maladies graves. Elle développe des remèdes basés sur l'acide ribonucléique messager (ARN messager, ou ARNm) pour une utilisation en tant qu'immunothérapie contre le cancer, en tant que vaccin contre les maladies infectieuses et en tant que thérapie de remplacement des protéines pour maladies rares, ainsi que pour la thérapie cellulaire, les nouveaux anticorps et petites molécules immunomodulateurs comme options de traitement du cancer. La société a mis au point une thérapie humaine à base d'ARNm pour administration intraveineuse afin d'amener l'immunothérapie anticancéreuse individualisée à base d'ARNm à des essais cliniques. Elle a établi son propre processus de fabrication. En 2020, le vaccin candidat de la société pour la prévention de la maladie à coronavirus 2019 (COVID-19), le Tozinaméran (BNT162b2), est un des premiers vaccins en essais cliniques de phase III en Chine et aux États-Unis. Un partenariat est mis en place avec Pfizer en septembre 2020. De nombreux chercheurs travaillent en 2020 à la mise au point de ce vaccin.
Abstract from DBpedia / Wikipedia · CC BY-SA
Gallery (3)
On the map
14 mapped locations